These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

22 related articles for article (PubMed ID: 8957053)

  • 1. A cost-effectiveness analysis of OKT3 induction therapy in cadaveric kidney transplantation.
    Shield CF; Jacobs RJ; Wyant S; Das A
    Am J Kidney Dis; 1996 Jun; 27(6):855-64. PubMed ID: 8651251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk-benefit of OKT3 prophylaxis in immunologic high-risk cadaver kidney transplant recipients.
    Cogny-Van Weydevelt F; Prud'Homme L; Boucher A; Dandavino R
    Transplant Proc; 1997 Nov; 29(7A):32S-34S. PubMed ID: 9366926
    [No Abstract]   [Full Text] [Related]  

  • 3. Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation.
    Desai DM; Scandling JD; Knoppel C; Dafoe DC; Alfrey EJ
    Transplant Proc; 1998 Jun; 30(4):1552-4. PubMed ID: 9636630
    [No Abstract]   [Full Text] [Related]  

  • 4. One center's experience with OKT3 in renal transplantation: patient and graft survival, complications, and cost analysis.
    Güz G; Emiroğlu R; Demirhan B; Köseoğlu F; Karakayali H; Bilgin N
    Transplant Proc; 2000 May; 32(3):572-3. PubMed ID: 10812117
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of OKT3 in steroid-resistant rejections following cadaveric kidney transplantation.
    Rosenkranz B; Niebel W; Albrecht K; Wagner K; Philipp T; Eigler FW
    Transpl Int; 1992; 5 Suppl 1():S112-3. PubMed ID: 14621750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muromonab-CD3 and antithymocyte globulin in renal transplantation.
    Burk ML; Matuszewski KA
    Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into therapy with monoclonal antibodies in allograft transplantation.
    Schena FP
    Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230
    [No Abstract]   [Full Text] [Related]  

  • 8. [Immunosuppressive treatment following kidney transplantation].
    Griebsch I
    Pharm Unserer Zeit; 2005; 34(4):322-30. PubMed ID: 16041960
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of OKT3 induction therapy in cadaveric kidney transplantation.
    Alsina J; Bover J; Grinyó JM
    Am J Kidney Dis; 1996 Dec; 28(6):958. PubMed ID: 8957053
    [No Abstract]   [Full Text] [Related]  

  • 10. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
    Wilde MI; Goa KL
    Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.